Athenex Inc
F:2MT
We don't have any information about 2MT's stock splits.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Feb 20, 2026
|
S
|
Samyang NC Chem Corp
KOSDAQ:482630
|
2-for-1
x2
|
40700 20350 KRW | 22650 22650 KRW |
|
Feb 20, 2026
|
|
Park Ha Biological Technology Co Ltd
NASDAQ:BYAH
|
1-for-50
/50
|
0.051 2.55 USD | 2.28 2.28 USD |
|
Feb 20, 2026
|
|
Brixton Metals Corp
OTC:BBBXF
|
1-for-10
/10
|
0.07 0.7 USD | 0.7 0.7 USD |
|
Feb 20, 2026
|
|
Shanghai Zhida Technology Development Co Ltd
HKEX:2650
|
5-for-1
x5
|
1327 265.4 HKD | 250 250 HKD |
|
Feb 20, 2026
|
|
Planet Ventures Inc
OTC:PNXPF
|
1-for-2
/2
|
0.161 0.161 USD | N/A |
BYAH
BBBXF
2650
PNXPF
Athenex Inc
Glance View
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. The company is headquartered in Buffalo, New York and currently employs 652 full-time employees. The company went IPO on 2017-06-14. The Company’s platforms include Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. Oncology Innovation Platform is engaged in research and development of its drugs. Global Supply Chain Platform is engaged in supplying active pharmaceutical ingredient to clinical and commercial efforts. Commercial Platform includes specialty pharmaceuticals business, and manufacture and marketing of products. The Company’s product pipeline includes Orascovery, Src Kinase Inhibition, Cell Therapy and Arginine Deprivation Therapy. Its lead product candidate Orascovery platform technology is based on the oral P-gp pump inhibitor molecule, encequidar. The Src Kinase inhibition platform technology is based on small molecule compounds including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization.
